 LAVAL, QC , ROCKVILLE, MD and CAMBRIDGE, United Kingdom , Jan. 13, 2020 CNW Telbec - Liminal BioSciences Inc. LMNL.TO LMNL.TO Liminal BioSciences or the Company , a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today provided a corporate update and outlined its key corporate and RD; priorities for 2020. During 2019, Liminal BioSciences undertook the initial steps towards simplifying and transforming our business to focus our efforts on developing important new medicines for patients and building value for our shareholders, stated Kenneth Galbraith , Chief Executive Officer of Liminal BioSciences. 